Symptoms and General Pathology

All Conditions

Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Syndrome

Polycystic Ovary Syndrome

Cysts

Ovarian Cysts

Ovarian Diseases

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Gonadal Disorders

Endocrine System Diseases

All Drugs and Chemicals

Hormones

Hormone Antagonists

IV administration of kisspeptin 112-121; 24-hour infusion. IV administration of GnRH; up to one bolus.

IV infusion of kisspeptin 112-121 x 24 hours; up to two IV boluses of kisspeptin

kisspeptin 112-121

GnRH

Study Coordinator

Stephanie B Seminara, MD

The goal of this study is to assess response to kisspeptin as well as the baseline patterns of luteinizing hormone (LH) secretion in individuals with polycystic ovarian syndrome (PCOS).

Assignment: All study subjects will undergo the same interventions. Baseline LH secretion patterns of individuals with PCOS will be compared to their LH secretion patterns while receiving a kisspeptin infusion.

Delivery of Interventions:

* Prior to the inpatient study visit, the subjects will undergo a review of their medical history, physical exam, and screening laboratories.
* On the day of the study, the subjects will have an intravenous (IV) line placed and

  * Undergo up to q10 min blood sampling x 36 hours
  * Receive an infusion of kisspeptin x 24 hours
  * Receive up to two kisspeptin IV boluses
  * Receive up to one gonadotropin-releasing hormone (GnRH) IV bolus

Dampening the Reproductive Axis With Continuous Kisspeptin

Average change in LH pulse frequency before and during kisspeptin infusion

Average change in LH pulse amplitude before and during kisspeptin infusion

Stephanie B. Seminara, MD

Chief, Reproductive Endocrine Unit; Professor of Medicine, Harvard Medical School; Director, MGH Harvard Center for Reproductive Medicine

Nervous System Diseases

Diseases and Abnormalities at or Before Birth

Rare Diseases

Hypogonadism

Hyperprolactinemia

Kallmann Syndrome

Pituitary Diseases

Hypothalamic Diseases

Brain Diseases

Central Nervous System Diseases

Disorders of Sex Development

Disorder of Sex Development, 46,XY

Congenital Abnormalities

Urogenital Abnormalities

Male Urogenital Diseases

Genetic Diseases, Inborn

Galactorrhoea-Hyperprolactinaemia

Intravenous (IV) or subcutaneous (SC) administration of kisspeptin 112-121 and/or administration of GnRH

One or more IV or SC doses of kisspeptin 112-121, and/or short infusion (up to 12 hours) of kisspeptin 112-121

One or more IV doses of GnRH, and/or SC administration of GnRH

Yee-Ming Chan, MD, PhD

Margaret Lippincott, MD

The goal of this study is to learn about the role of kisspeptin in the reproductive system. Kisspeptin is a naturally occurring hormone in humans that causes the release of other hormones, including gonadotropin-releasing hormone (GnRH) in the body.

The reproductive hormone GnRH is essential for normal reproductive function. People with idiopathic hypogonadotropic hypogonadism (IHH), hyperprolactinemia, and polycystic ovarian syndrome (PCOS) do not secrete or respond to GnRH in a normal way. In this study, investigators will give participants kisspeptin-a hormone that is naturally found in the human body and is known to be a powerful stimulus of GnRH secretion. They may also give participants GnRH to determine if participants will be able to fully respond to kisspeptin. The goal of this study is to use kisspeptin administration to probe the condition of GnRH neurons in people with various reproductive disorders to better understand the underlying reasons for the disorders. Investigators hope to gain new insights into GnRH neuronal function (or dysfunction) that will lead to better diagnostics in the future.

Kisspeptin Administration in the Adult

Administration of Kisspeptin to Subjects With Reproductive Disorders

Massachusetts General Hospital

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Dampening the Reproductive Axis With Continuous Kisspeptin	NCT05971849	Reproductive Di... PCOS Polycystic Ovar...	kisspeptin 112-... GnRH	18 Years - 45 Years	Massachusetts General Hospital
Kisspeptin Administration in the Adult	NCT00914823	Hypogonadotropi... Kallmann Syndro... GnRH Deficiency PCOS Polycystic Ovar... Hyperprolactine...	kisspeptin 112-... GnRH	18 Years -	Massachusetts General Hospital
Dampening the Reproductive Axis With Continuous Kisspeptin	NCT05971849	Reproductive Di... PCOS Polycystic Ovar...	kisspeptin 112-... GnRH	18 Years - 45 Years	Massachusetts General Hospital

Spots Global Cancer Trial Database for kisspeptin

Every month we try and update this database with for kisspeptin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for kisspeptin

Every month we try and update this database with for kisspeptin cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for kisspeptin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.